Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Has Average Target Price of $263.15

Revolution Medicines, Inc. (NASDAQ:RVMD) has been assigned a consensus rating of “Moderate Buy” from the twenty-four brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, twenty-one have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $263.15.

Several research analysts have commented on RVMD shares. UBS Group boosted their price objective on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, August 28th. TD Cowen increased their target price on shares of Revolution Medicines from $250.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Bank of America reduced their price target on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating on the stock in a research note on Friday, October 9th. Stifel Nicolaus lifted their price target on shares of Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Finally, Evercore reiterated an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th.

Revolution Medicines Stock Performance

Shares of Revolution Medicines stock opened at $193.06 on Friday. The firm has a 50-day moving average of $196.48 and a 200-day moving average of $158.35. Revolution Medicines has a 52-week low of $62.29 and a 52-week high of $224.31. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.36 and a quick ratio of 8.34.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to the consensus estimate of $25.58 million. During the same period in the prior year, the firm earned ($1.61) EPS. As a group, equities analysts forecast that Revolution Medicines will post -7.68 earnings per share for the current fiscal year.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across several periods, including projecting FY2027 EPS of $0.20 versus its prior estimate of a $6.86 loss. It maintained a Buy rating and a $350 price target. These forecasts imply a notably improved earnings outlook, although they are analyst projections, not company guidance. MarketBeat analyst estimates
• Positive Sentiment: A Zacks report cited a consensus price target implying 33.3% upside and said upward earnings-estimate revisions may be a near-term positive. It also cautioned that price targets alone have limited predictive value. Zacks analyst outlook
• Neutral Sentiment: A short-interest update described a significant increase but reported zero shares sold short and zero days to cover. Those figures conflict, so the update offers no clear signal about positioning.

Insider Activity

In other news, COO Margaret A. Horn sold 4,967 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $989,625.08. Following the completion of the transaction, the chief operating officer owned 149,680 shares of the company’s stock, valued at $29,822,243.20. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 4,053 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $807,519.72. Following the completion of the transaction, the chief financial officer owned 119,216 shares of the company’s stock, valued at approximately $23,752,595.84. This trade represents a 3.29% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 290,991 shares of company stock valued at $59,422,765. 7.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Revolution Medicines

Large investors have recently modified their holdings of the business. Ieq Capital LLC increased its stake in shares of Revolution Medicines by 19.5% in the third quarter. Ieq Capital LLC now owns 70,286 shares of the company’s stock valued at $14,427,000 after buying an additional 11,452 shares during the period. Focus Advisor Solutions LLC grew its holdings in Revolution Medicines by 281.7% during the 3rd quarter. Focus Advisor Solutions LLC now owns 6,225 shares of the company’s stock worth $1,278,000 after acquiring an additional 4,594 shares during the period. Independent Advisor Alliance grew its holdings in Revolution Medicines by 5.1% during the 3rd quarter. Independent Advisor Alliance now owns 1,764 shares of the company’s stock worth $355,000 after acquiring an additional 85 shares during the period. Voya Investment Management LLC raised its position in shares of Revolution Medicines by 103.2% in the 3rd quarter. Voya Investment Management LLC now owns 317,399 shares of the company’s stock worth $65,149,000 after acquiring an additional 161,230 shares in the last quarter. Finally, Global Retirement Partners LLC raised its position in shares of Revolution Medicines by 28.9% in the 3rd quarter. Global Retirement Partners LLC now owns 1,688 shares of the company’s stock worth $346,000 after acquiring an additional 378 shares in the last quarter. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.